GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0008625 | Stomach | GC | extrinsic apoptotic signaling pathway via death domain receptors | 14/1159 | 82/18723 | 4.71e-04 | 6.84e-03 | 14 |
GO:00310325 | Stomach | GC | actomyosin structure organization | 25/1159 | 196/18723 | 4.72e-04 | 6.84e-03 | 25 |
GO:00433936 | Stomach | GC | regulation of protein binding | 25/1159 | 196/18723 | 4.72e-04 | 6.84e-03 | 25 |
GO:00106396 | Stomach | GC | negative regulation of organelle organization | 38/1159 | 348/18723 | 4.87e-04 | 7.04e-03 | 38 |
GO:1903409 | Stomach | GC | reactive oxygen species biosynthetic process | 12/1159 | 64/18723 | 4.90e-04 | 7.07e-03 | 12 |
GO:20000586 | Stomach | GC | regulation of ubiquitin-dependent protein catabolic process | 22/1159 | 164/18723 | 5.05e-04 | 7.16e-03 | 22 |
GO:00428863 | Stomach | GC | amide transport | 34/1159 | 301/18723 | 5.16e-04 | 7.28e-03 | 34 |
GO:00300105 | Stomach | GC | establishment of cell polarity | 20/1159 | 143/18723 | 5.20e-04 | 7.33e-03 | 20 |
GO:00616875 | Stomach | GC | detoxification of inorganic compound | 6/1159 | 18/18723 | 5.40e-04 | 7.55e-03 | 6 |
GO:01201924 | Stomach | GC | tight junction assembly | 13/1159 | 74/18723 | 5.60e-04 | 7.80e-03 | 13 |
GO:00108116 | Stomach | GC | positive regulation of cell-substrate adhesion | 18/1159 | 123/18723 | 5.62e-04 | 7.81e-03 | 18 |
GO:00516423 | Stomach | GC | centrosome localization | 8/1159 | 32/18723 | 5.82e-04 | 7.99e-03 | 8 |
GO:00442824 | Stomach | GC | small molecule catabolic process | 40/1159 | 376/18723 | 5.92e-04 | 8.09e-03 | 40 |
GO:0042098 | Stomach | GC | T cell proliferation | 25/1159 | 199/18723 | 5.92e-04 | 8.09e-03 | 25 |
GO:00324346 | Stomach | GC | regulation of proteasomal ubiquitin-dependent protein catabolic process | 19/1159 | 134/18723 | 5.98e-04 | 8.14e-03 | 19 |
GO:00308665 | Stomach | GC | cortical actin cytoskeleton organization | 9/1159 | 40/18723 | 6.17e-04 | 8.31e-03 | 9 |
GO:00434345 | Stomach | GC | response to peptide hormone | 43/1159 | 414/18723 | 6.20e-04 | 8.32e-03 | 43 |
GO:0042180 | Stomach | GC | cellular ketone metabolic process | 26/1159 | 211/18723 | 6.25e-04 | 8.37e-03 | 26 |
GO:0002687 | Stomach | GC | positive regulation of leukocyte migration | 19/1159 | 135/18723 | 6.56e-04 | 8.76e-03 | 19 |
GO:0070661 | Stomach | GC | leukocyte proliferation | 35/1159 | 318/18723 | 6.92e-04 | 9.20e-03 | 35 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AR | SNV | Missense_Mutation | | c.2595N>A | p.Asp865Glu | p.D865E | P10275 | protein_coding | deleterious(0) | probably_damaging(0.923) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
AR | SNV | Missense_Mutation | | c.1912N>A | p.Leu638Met | p.L638M | P10275 | protein_coding | tolerated(0.07) | benign(0.316) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
AR | SNV | Missense_Mutation | novel | c.1082N>A | p.Ser361Asn | p.S361N | P10275 | protein_coding | tolerated_low_confidence(0.27) | benign(0.015) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1681N>A | p.Leu561Met | p.L561M | P10275 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-BH-A18L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1703C>T | p.Ser568Phe | p.S568F | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
AR | SNV | Missense_Mutation | novel | c.2642N>A | p.Leu881Gln | p.L881Q | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-OL-A66K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | novel | c.585N>T | p.Gln195His | p.Q195H | P10275 | protein_coding | tolerated_low_confidence(0.13) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.2718N>T | p.Lys906Asn | p.K906N | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.967N>A | p.Glu323Lys | p.E323K | P10275 | protein_coding | tolerated_low_confidence(0.11) | benign(0.265) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
AR | SNV | Missense_Mutation | | c.2462G>T | p.Gly821Val | p.G821V | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | FLUOCINOLONE ACETONIDE | FLUOCINOLONE ACETONIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 4-CHLOROMERCURIBENZOIC ACID | 4-CHLOROMERCURIBENZOIC ACID | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | agonist | CHEMBL2107067 | TESTOSTERONE UNDECANOATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | DIDECYLDIMETHYLAMMONIUM CHLORIDE | DIDECYLDIMETHYLAMMONIUM CHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | QUININE SULFATE | QUININE SULFATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | NILUTAMIDE | NILUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | RALOXIFENE HYDROCHLORIDE | RALOXIFENE HYDROCHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | ARN-509 | APALUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | CRUFOMATE | CRUFOMATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 2-AMINOFLURENE | CHEMBL84472 | |